Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Orthopoxviruses
3. Why are antiviral therapies required?
4. Replication of orthopoxviruses
5. Properties of an ideal drug
6. Inhibitors of orthopoxvirus replication
7. Potential candidates
8. Animal models for anti-orthopoxvirus drugs
9. Efficacy against vaccinia virus and cowpox virus
10. Cidofovir (CDV)
11. Mechanism of action of CDV
12. Interval of CDV treatment against cowpox virus
13. Single dose CDV affects mortality of cowpox virus
14. Single dose CDV affects mortality of vaccinia virus
15. Parenteral or topical CDV affect virus titers
16. Vaccinia virus (VV) titers after topical/i.p. CDV
17. CMX001
18. Phosphonate nucleotides and alkoxyalkyl analogs
19. Effects of HDP-CDV/ODE-CDV on mortality on VV
20. Effects of oral treatment with CMX001 on VV
21. Effect of daily oral HDP-CDV/ODE-CDV - Cowpox
22. Effect of daily oral HDP-CDV/ODE-CDV - Vaccinia
23. Effect of oral CMX001 on ectromelia virus (ECTV)
24. Efficacy of oral CMX001 in rabbitpox virus
25. CMX001 and CDV pharmacokinetic studies
26. ST-246 (tecovirimat)
27. Inhibition of extracellular virus formation by ST-246
28. Delayed ST-246 treatment - Cowpox virus
29. Once-daily oral ST-246 treatment - Cowpox virus
30. Once-daily oral ST-246 treatment - Vaccinia virus
31. Delayed treatment with ST-246 - ECTV
32. Twice-daily treatment with ST-246 - ECTV
33. Once-daily treatment with ST-246 - ECTV
34. Summary of ST-246 efficacy
35. 4'-thioIDU
36. Efficacy and toxicity of 4'-thioIDU
37. Activity of 4'-thioIDU - WT and resistant VV
38. Role of TK in 4'-thioIDU activity - Cowpox virus
39. Mutant resistant to 4'-thioIDU
40. Selection of a 4'-thioIDU resistant mutant
41. Viral TK homologs
42. Crystal structure of VV TK
43. TK active sites in human and vaccinia
44. Kinetic parameters for TK substrates
45. 4'-thioIDU incorporation into viral DNA
46. Oral treatment with 4'-thioIDU in CV
47. Oral treatment with 4'-thioIDU in VV
48. Combination chemotherapy
49. CMX001 and ST-246 against CV and VV
50. Oral CMX001 and ST-246 treatment of CV
51. 4'-thioIDU potentiates CMX001 and ST-246 activity
52. Clinical development
53. Summary
54. Acknowledgments

Topics Covered

• Orthopoxviruses that infect humans
• Effective antiviral therapies
• Development of CMX001
• Development of ST-246
• Mechanism of action of drugs

Links

Series:

• Antivirals

Categories:

• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Kern, E.R. and Prichard, M.N. (2011, August 31). Antiviral therapy of orthopoxvirus infection [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/YMWT4494.
Export Citation (RIS)

Publication History

• Published on August 31, 2011

Financial Disclosures

• Prof. Earl R. Kern has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
• Prof. Mark N. Prichard has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.